Activity of Rezafungin Against Echinocandin Non-wild type <i>Candida glabrata</i> Clinical Isolates From a Global Surveillance Program. [PDF]
Open Forum Infect DisAmong 1463 Candida glabrata isolates collected in 39 US hospitals, 91 (6.2%) were non–wild type to ≥1 echinocandins (ECH-NWT) when tested by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpretative ...
Castanheira M +3 more
europepmc +2 more sources
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician [PDF]
Infection and Drug Resistance, 2023 Frederic Lamoth1,2 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University ...
Lamoth F
doaj +3 more sources
Necrotizing gingival infection due to in an hematopoietic stem cell transplant recipient: case report [PDF]
Therapeutic Advances in Infectious DiseaseTrichoderma is a genus of rare filamentous fungi that can cause invasive fungal infections in immunocompromised patients. We report a case of necrotizing gingival and sinus infection due to T.
Eduardo Aparicio-Minguijón +7 more
doaj +2 more sources
Treatment of Candida glabrata native valve endocarditis with rezafungin: a case report. [PDF]
JAC-Antimicrobial ResistanceGiovanni Mori +4 more
semanticscholar +6 more sources
Rezafungin in special populations with candidaemia and/or invasive candidiasis.
Journal of InfectionAchieving and maintaining therapeutic drug exposures with antifungals can be challenging in special patient populations, such as those with organ dysfunction (liver or kidney) or obesity, or elderly patients, due to dose-exposure relationships and ...
Oliver A. Cornely +6 more
semanticscholar +3 more sources
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. [PDF]
Lancet. Infectious Diseases (Print), 2023 BACKGROUND Rezafungin, a new US Food and Drug Administration-approved, long-acting echinocandin to treat candidaemia and invasive candidiasis, was efficacious with a similar safety profile to caspofungin in clinical trials.
George R Thompson +16 more
semanticscholar +3 more sources
P-1034. Week One Outcomes of Rezafungin vs Caspofungin Treatment for Candidemia and Invasive Candidiasis (CIC): Pooled Analysis of Two Randomized Trials Exploring Optimal Echinocandin Duration [PDF]
Open Forum Infect DisBackground The Phase 2 STRIVE and Phase 3 ReSTORE trials demonstrated the efficacy and safety of rezafungin for treating CIC. With data suggesting early treatment benefit for rezafungin, possibly due to its front-loaded dosing, this pooled analysis of ...
Luis Ostrosky-Zeichner +2 more
europepmc +2 more sources
FDA‐approved drugs featuring macrocycles or medium‐sized rings [PDF]
Archiv der Pharmazie, Volume 358, Issue 1, January 2025.This review presents 17 macrocyclic drugs approved by the U.S. Food and Drug Administration during the past 5 years, highlighting their importance and critical role in modern therapeutics, and the innovative synthetic approaches for the construction of these macrocycles.
Youlong Du +7 more
wiley +3 more sources
International Journal of Infectious DiseasesRasamsonia argillacea species complex are emerging opportunistic molds increasingly reported in patients with chronic lung disease. We describe a 69-year-old woman with bronchiectasis who developed relapsing R. aegroticola pneumonia.
Hugo Bes-Berlandier +14 more
doaj +2 more sources
Journal of FungiObjectives: Rezafungin is the first new drug approved to treat candidaemia and invasive candidiasis in more than 10 years. However, data are scant on the in vivo efficacy of rezafungin and the other three approved echinocandins against different Candida ...
Dávid Balázsi +10 more
doaj +2 more sources